Last edition
News about "Progression-Free Survival"
ArriVent's FURVENT Phase 3 Trial Misses Primary PFS Endpoint
ArriVent’s FURVENT Phase 3 trial of firmonertinib in EGFR exon 20 insertion-mutant NSCLC did not meet its primary PFS endpoint.
Progression-Free Survival | 07/10/2026 | By News Bureau | 100
Astellas Advances Setidegrasib Into Phase 3 Trial for NSCLC
Astellas has dosed the first patient in a Phase 3 study evaluating setidegrasib against docetaxel in patients with KRAS G12D-mutated NSCLC.
Progression-Free Survival | 25/09/2026 | By News Bureau | 149
Roche's Lunsumio Combo Meets Phase 3 CELESTIMO Endpoint
Roche’s Phase 3 CELESTIMO study shows statistically significant, clinically meaningful improvement in PFS with Lunsumio plus lenalidomide in R/R follicular lymphoma.
Progression-Free Survival | 18/09/2026 | By News Bureau
AstraZeneca, Daiichi Sankyo's Enhertu Shows Superior PFS in First-Line HER2-Mutant NSCLC
DESTINY-Lung04 results showed Enhertu delivered a median PFS of 14.3 months versus 8.3 months with pembrolizumab plus chemotherapy in first-line HER2-mutant advanced NSCLC.
Progression-Free Survival | 16/09/2026 | By News Bureau | 115
Imfinzi-Tarlatamab Combination Improves Overall Survival in Phase 3 ES-SCLC Trial
AstraZeneca and Amgen reported statistically significant improvements in overall and progression-free survival with Imfinzi plus tarlatamab versus Imfinzi alone in the Phase 3 DeLLphi-305 trial.
Progression-Free Survival | 10/09/2026 | By News Bureau
BeOne Medicines reports positive Phase 3 results showing improved overall survival with Ziihera-based regimens in patients with HER2-positive gastroesophageal adenocarcinoma.
Progression-Free Survival | 01/09/2026 | By News Bureau
Laekna's LAE002 Breast Cancer Drug Application Accepted by China's NMPA
Laekna has advanced LAE002 toward potential commercialisation in China after the NMPA accepted its NDA for afuresertib in patients with advanced HR+/HER2- breast cancer.
Progression-free Survival | 12/08/2026 | By News Bureau | 171
Genprex has partnered with Roche Diagnostics to validate TROP2 biomarkers for patient selection in non-small cell lung cancer trials, aiming to accelerate precision medicine and improve treatment outcomes.
Progression-Free Survival | 04/08/2026 | By News Bureau | 103
AstraZeneca's investigational antibody-drug conjugate Sone-Ve demonstrated a significant overall survival benefit in the Phase 3 CLARITY-Gastric01 trial, marking a milestone in the development of targeted therapies for CLDN18.2-positive advanced gastric cancer.
Progression-Free Survival | 28/07/2026 | By News Bureau
Roche's Divarasib Outperforms First-Generation KRAS G12C Inhibitors in Phase 3 Lung Cancer Trial
Roche's investigational KRAS G12C inhibitor divarasib demonstrated superior progression-free and overall survival over approved first-generation therapies in the Phase III Krascendo 1 trial, marking a significant advance in the treatment of previously treated KRAS G12C-mutated non-small cell lung cancer.
Progression-Free Survival | 04/07/2026 | By News Bureau | 311
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy